'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 11, 2008, Pages 6242-6251

  Schultz, Danielle M ^a   Prescher, Jennifer A ^a   Kidd, Stephanie ^b   Marona Lewicka, Danuta ^b   Nichols, David E ^b   Monte, Aaron ^a  

^a UNIVERSITY OF WISCONSIN LA CROSSE   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

5 HT receptor agonist; Hallucinogen; Phenethylamines; Structure activity relationship

Indexed keywords

1 (4 BROMO 3,6,7,8 TETRAHYDRO 2H FURO[2,3 G]CHROMEN 9 YL)PROPAN 2 AMINE; 1 (9 BROMO 3,6,7,8 TETRAHYDRO 2H FURO[2,3 G]CHROMEN 4 YL)PROPAN 2 AMINE; 2 (4 BROMO 3,6,7,8 TETRAHYDRO 2H FURO[2,3 G]CHROMEN 9 YL)ETHANAMINE; 2 (9 BROMO 3,6,7,8 TETRAHYDRO 2H FURO[2,3 G]CHROMEN 4 YL)ETHANAMINE; 8 BROMO 1 (2,3,6,7 TETRAHYDROBENZO[1,2 B:4,5 B']DIFURAN 4 YL) 2 AMINOPROPANE; AMPHETAMINE; BENZOFURAN DERIVATIVE; BENZOPYRAN DERIVATIVE; LYSERGIDE; PHENETHYLAMINE DERIVATIVE; PSYCHEDELIC AGENT; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DISCRIMINATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; RAT;

2,5-DIMETHOXY-4-METHYLAMPHETAMINE; ANIMALS; BENZOFURANS; BENZOPYRANS; HALLUCINOGENS; LIGANDS; MALE; PHENETHYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; STEREOISOMERISM;

RATTUS;

EID: 44449137473     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.04.030     Document Type: Article

References (25)

1. Nichols D.E. Pharmacol. Ther. 101 (2004) 131-181
2. Chambers J.J., and Nichols D.E. J. Comput. Aided Mol. Des. 16 (2002) 511-520
3. McLean T.H., Parrish J.C., Braden M.R., Marona-Lewicka D., Gallardo-Godoy A., and Nichols D.E. J. Med. Chem. 49 (2006) 5794-5803
4. McLean T.H., Chambers J.J., Parrish J.C., Braden M.R., Marona-Lewicka D., Kurrasch-Orbaugh D., and Nichols D.E. J. Med. Chem. 49 (2006) 4269-4274
5. Braden M.R., and Nichols D.E. Mol. Pharmacol. 72 (2007) 1200-1209
6. Monte A.P., Marona-Lewicka D., Parker M.A., Wainscott D.B., Nelson D.L., and Nichols D.E. J. Med. Chem. 39 (1996) 2953-2961
7. Whiteside M.S., Kurrasch-Orbaugh D., Marona-Lewicka D., Nichols D.E., and Monte A. Bioorg. Med. Chem. 10 (2002) 3301-3306
8. Parrish J.C., Braden M.R., Gundy E., and Nichols D.E. J. Neurochem. 95 (2005) 1575-1584
9. Parker M.A., Marona-Lewicka D., Lucaites V.L., Nelson D.L., and Nichols D.E. J. Med. Chem. 41 (1998) 5148-5149
10. Brown H.C., Krishnamurthy S., and Yoon N.M. J. Org. Chem. 41 (1976) 1778-1791
11. Bhatt M.V. J. Organomet. Chem. 156 (1978) 221-226
12. Still W.C., Kahn M., and Mitra A. J. Org. Chem. 43 (1978) 2923-2925
13. Kurrasch-Orbaugh D.M., Watts V.J., Barker E.L., and Nichols D.E. J. Pharmacol. Exp. Ther. 304 (2003) 229-237
14. Appel J.B., and Cunningham K.A. Psychopharmacol. Bull. 22 (1986) 959-967
15. Arnt J. Pharmacol. Toxicol. 64 (1989) 165-172
16. Glennon R.A., Rosecrans J.A., and Young R. Med. Res. Rev. 3 (1983) 289-340
17. Cunningham K.A., and Appel J.B. Psychopharmacology 91 (1987) 67-73
18. Nielsen E.J. J. Pharmacol. Exp. Ther. 234 (1985) 244-249
19. Chambers J.J., Kurrasch-Orbaugh D.M., Parker M.A., and Nichols D.E. J. Med. Chem. 44 (2001) 1003-1010
20. Litchfield J.T., and Wilcoxon F.A. J. Pharmacol. Exp. Ther. 96 (1949) 99-112
21. Pomilio A.B., and Tettamanzi M.C. Magn. Reson. Chem. 34 (1996) 165-171
22. Harwood L.M. Aldrichim. Acta 18 (1985) 25
23. Braden M.R., Parrish J.C., Naylor J.C., and Nichols D.E. Mol. Pharmacol. 70 (2006) 1956-1964
24. Chambers J.J., Kurrasch-Orbaugh D.M., and Nichols D.E. Bioorg. Med. Chem. Lett. 12 (2002) 1997-1999
25. Marona-Lewicka D., Thisted R.A., and Nichols D.E. Psychopharmacology 180 (2005) 427-435